Cited by 367Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

α-Synucleinopathy phenotypes

Open access

McCann, Heather, Stevens, Claire H., Cartwright, Heidi, Halliday, Glenda M.·2014·Parkinsonism & Related Disorders

DOI 10.1016/s1353-8020(13)70017-8

Open this paper in CoChat — free account Open PDF

Abstract

α-Synucleinopathies are neurodegenerative diseases characterised by the abnormal accumulation of α-synuclein aggregates in neurons, nerve fibres or glial cells. While small amounts of these α-synuclein pathologies can occur in some neurologically normal individuals who do not have associated neurodegeneration, the absence of neurodegeneration in such individuals precludes them from having a degenerative α-synucleinopathy, and it has yet to be established whether such individuals have a form of preclinical disease. There are three main types of α-synucleinopathy, Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), with other rare disorders also having α-synuclein pathologies, such as various neuroaxonal dystrophies. Multiple clinical phenotypes exist for each of the three main α-synucleinopathies, with these phenotypes differing in the dynamic distribution of their underlying neuropathologies. Identifying the factors involved in causing different α-synuclein phenotypes may ultimately lead to more targeted therapeutics as well as more accurate clinical prognosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1353-8020(13)70017-8

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figure 2 Diagram illustrating the different pathological types of cases meeting clinical criteria for Parkinson's disease with dementia (PDD), dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Lewy-related pathologies (LRP) identified in sections from the temporal cortex and amygdala stained for α-synuclein immunohistochemistry and counterstained with cresyl violet. Plaques are identified in sections from temporal cortex stained for amyloid β immunohistochemistry and counterstained with cresyl violet. Neurofibrillary tangles (NFTs) identified in sections from the temporal cortex stained with a modified Bielschowsky silver stain.CC-BY-NC-ND · From the PDF

Figure 3 Photomicrographs of the substantia nigra (SN in A-D), putamen (E-H) and cerebellum (I-L) of representative controls (A, E, I) and cases with early and mild (B, F, J) or late and severe (C, G, K) MSA. Cases with MSA-P have substantial degeneration in the putamen (F, G) in addition to the substantia nigra (B, C), while cases with MSA-C have substantial degeneration in the cerebellum (J, K) in addition to the substantia nigra (B, C), as shown in haematoxylin and eosin stained sections. αSynuclein immunoreactive glial cytoplasmic inclusions are observed in all regions of neurodegeneration in MSA (D, H, L). cp=cerebral peduncle.CC-BY-NC-ND · From the PDF

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citation
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Second consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,346
Self-citation
Identification of two distinct synucleins from human brain
Jakes, R., Spillantini, M. G., & Goedert, M. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00395-5 · Cited by 1,080
Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry
Hamilton, R. L. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00269.x · Cited by 754
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W. H., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 615

Show all 32 references

Sorted by citations

Items 101–200 of 367

The differential solvent exposure of N-terminal residues provides “fingerprints” of alpha-synuclein fibrillar polymorphs
Landureau, M., Redeker, V., Bellande, T., Eyquem, S., & Melki, R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100737 · Cited by 40
Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols
Herman, F. J., Westfall, S., Brathwaite, J. S., & Pasinetti, G. M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00867 · Cited by 43
Transcellular propagation of fibrillar α-synuclein from enteroendocrine to neuronal cells requires cell-to-cell contact and is Rab35-dependent
Rodrigues, P. V., de Godoy, J. V. P., Bosque, B. P., Neto, D. P. A., Tostes, K., Palameta, S., Garcia-Rosa, S., Tonoli, C. C. C., Carvalho, H. F., & Fonseca, M. D. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-08076-5 · Cited by 40
Towards translational therapies for multiple system atrophy
Kuzdas-Wood, D., Stefanova, N., Jellinger, K. A., Seppi, K., Schlossmacher, M. G., Poewe, W. H., & Wenning, G. K. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.007 · Cited by 39
CSF biomarkers in neurodegenerative and vascular dementias
Llorens, F., Schmitz, M., Ferrer, I., & Zerr, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.003 · Cited by 44
RETRACTED ARTICLE: Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells
Kim, C., Kwon, S., Iba, M., Spencer, B. J., Rockenstein, E. M., Mante, M., Adame, A., Shin, S. J., Fields, J. A., Rissman, R. A., et al. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00562-6 · Cited by 42
Retracted
The Roles of Peroxiredoxin 6 in Brain Diseases
Liao, J., Zhang, Y., Chen, X., & Zhang, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02427-5 · Cited by 39
A Novel Brain PET Radiotracer for Imaging Alpha Synuclein Fibrils in Multiple System Atrophy
Kim, H. Y., Chia, W. K., Hsieh, C., Guarino, D. S., Graham, T. J. A., Lengyel‐Zhand, Z., Schneider, M., Tomita, C., Lougee, M. G., Kim, H. J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00779 · Cited by 38
Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies
Labbé, C., Ogaki, K., Lorenzo‐Betancor, O., Soto‐Ortolaza, A. I., Walton, R. L., Rayaprolu, S., Fujioka, S., Murray, M. E., Heckman, M. G., Puschmann, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001946 · Cited by 38
In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies
Marvian, A. T., Koss, D. J., Aliakbari, F., Morshedi, D., & Outeiro, T. F. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14707 · Cited by 38
Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight
Forloni, G., Vitola, P. L., Cerovic, M., & Balducci, C. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.11.001 · Cited by 41
α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response
Delaidelli, A., Richner, M., Jiang, L., van der Laan, A., Christiansen, I. B. J., Ferreira, N., Nyengaard, J. R., Vægter, C. B., Jensen, P. H., Mackenzie, I. R., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01209-3 · Cited by 39
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
Akter, R., Rahman, H., Behl, T., Chowdhury, M. A. R., Manirujjaman, M., Bulbul, I. J., Elshenawy, S. E., Ţiţ, D. M., & BUNGAU, S. G. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210218084444 · Cited by 40
A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease
Breitve, M. H., Chwiszczuk, L. J., Hynninen, M. J., Rongve, A., Brønnick, K., Janvin, C. C., & Aarsland, D. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0053-6 · Cited by 37
Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid
Boman, A., Svensson, S., Boxer, A. L., Rojas, J. C., Seeley, W. W., Karydas, A., Miller, B. L., Kågedal, K., & Svenningsson, P. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150759 · Cited by 33
Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies
Kwon, S., Iba, M., Masliah, E., & Kim, C. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.5.547 · Cited by 35
Polarized α-synuclein trafficking and transcytosis across brain endothelial cells via Rab7-decorated carriers
Alam, P., Holst, M. R., Lauritsen, L., Nielsen, J., Nielsen, S. S. E., Jensen, P. H., Brewer, J. R., Otzen, D. E., & Nielsen, M. S. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00334-y · Cited by 32
α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
Bigi, A., Cascella, R., & Cecchi, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.371345 · Cited by 38
Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease
Yoo, H., Lee, J., Kim, B., Moon, H., Jeong, H., Lee, K., Song, W., Hur, J. K., & Oh, Y. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.7.073 · Cited by 35
Sex differences in alpha-synucleinopathies: a systematic review
Raheel, K., Deegan, G., Giulio, I. D., Cash, D., Ilić, K., Gnoni, V., Chaudhuri, К. R., Drakatos, P., Moran, R., & Rosenzweig, I. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1204104 · Cited by 33
Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies
Kalra, D. K., Raina, A., & Sohal, S. (2020) · Clinical Medicine Insights Cardiology · doi:10.1177/1179546820953415 · Cited by 33
Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
Jin, J. W., Fan, X., del Cid‐Pellitero, E., Liu, X., Zhou, L., Dai, C., Gibbs, E., He, W., Li, H., Wu, X., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01746-6 · Cited by 38
Autophagy in α-Synucleinopathies—An Overstrained System
Fellner, L., Gabassi, E., Haybaeck, J., & Edenhofer, F. (2021) · Cells · doi:10.3390/cells10113143 · Cited by 36
Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
Iba, M., Kim, C., Florio, J. B., Mante, M., Adame, A., Rockenstein, E. M., Kwon, S., Rissman, R. A., & Masliah, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00286 · Cited by 33
Retracted
Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson’s Disease
Miller, S., Campbell, C. E., Jimenez-Corea, H. A., Wu, G., & Logan, R. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824191 · Cited by 34
Profiling neuroprotective potential of trehalose in animal models of neurodegenerative diseases: a systematic review
Mustapha, M., Ibrahim, N. M., Yap, K. H., Azmin, S., Makpol, S., Damanhuri, H. A., & Hamzah, J. C. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.360164 · Cited by 32
Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy
Jennum, P., Pedersen, L. Ø., Bahl, J. M. C., Modvig, S., Fog, K., Holm, A., Kornum, B. R., & Gammeltoft, S. (2016) · SLEEP · doi:10.1093/sleep/zsw006 · Cited by 33
The impact of hUC MSC–derived exosome-nanoliposome hybrids on α-synuclein fibrillation and neurotoxicity
Aliakbari, F., Marzookian, K., Parsafar, S., Hourfar, H., Nayeri, Z., Fattahi, A., Raeiji, M., Boroujeni, N. N., Otzen, D. E., & Morshedi, D. (2024) · Science Advances · doi:10.1126/sciadv.adl3406 · Cited by 37
Parsing disease‐relevant protein modifications from epiphenomena: perspective on the structural basis of SOD1‐mediated ALS
Schmitt, N. D., & Agar, J. N. (2017) · Journal of Mass Spectrometry · doi:10.1002/jms.3953 · Cited by 29
Models of multiple system atrophy
Lee, H.-J., Ricarte, D., Ortiz, D. M., & Lee, S. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0346-8 · Cited by 33
The Role of Glial Mitochondria in α-Synuclein Toxicity
Jeon, Y., Kwon, Y., Jo, M., Lee, S., Kim, S., & Kim, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.548283 · Cited by 31
Conformational Ensembles of α-Synuclein Derived Peptide with Different Osmolytes from Temperature Replica Exchange Sampling
Jamal, S., Kumari, A., Singh, A. P., Goyal, S., & Grover, A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00684 · Cited by 29
Genes Implicated in Familial Parkinson’s Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage
Franco, R., Rivas‐Santisteban, R., Navarro, G., Pinna, A., & Reyes‐Resina, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094643 · Cited by 31
RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies
Poggiolini, I., Erskine, D., Vaikath, N. N., Ponraj, J., Mansour, S. A., Morris, C. M., & El‐Agnaf, O. M. A. (2021) · Biomolecules · doi:10.3390/biom11060820 · Cited by 27
Plasma sphingolipid abnormalities in neurodegenerative diseases
Oizumi, H., Sugimura, Y., Totsune, T., Kawasaki, I., Ohshiro, S., Baba, T., Kimpara, T., Sakuma, H., Hasegawa, T., Kawahata, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279315 · Cited by 31
PPARs and Their Neuroprotective Effects in Parkinson’s Disease: A Novel Therapeutic Approach in α-Synucleinopathy?
Pérez-Segura, I., Santiago-Balmaseda, A., Rodríguez-Hernández, L. D., Morales-Martínez, A., Martínez-Becerril, H. A., Martínez-Gómez, P. A., Delgado-Minjares, K. M., Salinas‐Lara, C., Martínez-Dávila, I. A., Guerra‐Crespo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043264 · Cited by 29
Copper(II) and the pathological H50Q α-synuclein mutant: Environment meets genetics
Villar‐Piqué, A., Rossetti, G., Ventura, S., Carloni, P., Fernández, C. O., & Outeiro, T. F. (2017) · Communicative & Integrative Biology · doi:10.1080/19420889.2016.1270484 · Cited by 28
Heterogeneity in α‐synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease
Vaikath, N. N., Erskine, D., Morris, C. M., Majbour, N. K., Vekrellis, K., Li, J., & El‐Agnaf, O. M. A. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12531 · Cited by 28
Exploring the Release of Toxic Oligomers from α-Synuclein Fibrils with Antibodies and STED Microscopy
Bigi, A., Ermini, E., Chen, S. W., Cascella, R., & Cecchi, C. (2021) · Life · doi:10.3390/life11050431 · Cited by 28
Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms
Wildburger, N. C., Hartke, A.-S., Schidlitzki, A., & Richter, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.598446 · Cited by 28
Neuroinflammation Upregulated Neuronal Toll-Like Receptors 2 and 4 to Drive Synucleinopathy in Neurodegeneration
Chung, L. Y.-R., Lin, Y., Liu, C., Tai, Y., Lin, H., Lin, C., & Chen, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.845930 · Cited by 30
Role of endolysosomes and inter-organellar signaling in brain disease
Afghah, Z., Chen, X., & Geiger, J. D. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104670 · Cited by 27
The role of alpha-synuclein in synucleinopathy: Impact on lipid regulation at mitochondria–ER membranes
Barbuti, P. A., Guardia‐Laguarta, C., Yun, T., Chatila, Z. K., Flowers, X. E., Wong, C., Santos, B. F. R., Larsen, S. B., Lotti, J. S., Hattori, N., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00960-x · Cited by 31
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology
Teil, M., Doveró, S., Bourdenx, M., Arotçarena, M.-L., Camus, S. M. J., Porras, G., Thiolat, M.-L., Trigo‐Damas, I., Perier, C., Estrada, C. M., et al. (2021) · Brain · doi:10.1093/brain/awab374 · Cited by 28
Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis
Bräuer, S., Zimyanin, V. L., & Hermann, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1851-y · Cited by 29
Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species
Singh, P., & Bhat, R. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00650 · Cited by 25
Structures prediction and replica exchange molecular dynamics simulations of α-synuclein: A case study for intrinsically disordered proteins
Coskuner‐Weber, O. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133813 · Cited by 26
Positron emission tomography tracers for synucleinopathies
Xiang, J., Zhang, Z., Wu, S., & Ye, K. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00787-9 · Cited by 27
Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases
(APMI), F. T. A. P. M. I., Baldacci, F., Lista, S., O’Bryant, S. E., Ceravolo, R., Toschi, N., & Hampel, H. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_9 · Cited by 23
Plasma cytokine profile in synucleinophaties with dementia
Usenko, T. S., Nikolaev, M. A., Miliukhina, I. V., Bezrukova, A. I., Senkevich, K. A., Gomzyakova, N. A., Beltceva, I. A., Zalutskaya, N. M., Gracheva, E., Timofeeva, A., et al. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.04.058 · Cited by 25
Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism
Constantinescu, R., Rosengren, L., Eriksson, B., Blennow, K., & Axelsson, M. (2019) · Acta Neurologica Scandinavica · doi:10.1111/ane.13116 · Cited by 24
Molecular mechanism of α-synuclein aggregation on lipid membranes revealed
Dear, A. J., Teng, X., Ball, S. R., Lewin, J., Horne, R. I., Clow, D., Stevenson, A., Harper, N., Yahya, K., Yang, X., et al. (2024) · Chemical Science · doi:10.1039/d3sc05661a · Cited by 25
Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson’s disease
Yeni, Y., Genç, S., Ertuğrul, M. S., Nadaroğlu, H., Gezer, A., Mendĭl, A. S., & Hacımüftüoğlu, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-69324-4 · Cited by 26
Postmortem Brain Imaging in Alzheimer’s Disease and Related Dementias: The South Texas Alzheimer’s Disease Research Center Repository
Li, K., Rashid, T., Li, J., Honnorat, N., Nirmala, A. B., Fadaee, E., Wang, D., Charisis, S., Liu, H., Franklin, C. G., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230389 · Cited by 25
A Focus on the Beneficial Effects of Alpha Synuclein and a Re-Appraisal of Synucleinopathies
Ryskalin, L., Busceti, C. L., Limanaqi, F., Biagioni, F., Gambardella, S., & Fornai, F. (2017) · Current Protein and Peptide Science · doi:10.2174/1389203718666171117110028 · Cited by 23
Celecoxib promotes survival and upregulates the expression of neuroprotective marker genes in two different in vitro models of Parkinson's disease
Dassati, S., Schweigreiter, R., Buechner, S., & Waldner, A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108378 · Cited by 22
α-Synuclein Regulates Development and Function of Cholinergic Enteric Neurons in the Mouse Colon
Swaminathan, M., Fung, C., Finkelstein, D. I., Bornstein, J. C., & Foong, J. P. P. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.10.029 · Cited by 23
Fatty Acid-Binding Protein 3 Expression in the Brain and Skin in Human Synucleinopathies
Oizumi, H., Yamasaki, K., Suzuki, H., Hasegawa, T., Sugimura, Y., Baba, T., Fukunaga, K., & Takeda, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.648982 · Cited by 22
Cellular Models for the Study of PrionsPreprint
Holmes, B. B., & Diamond, M. I. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024026 · Cited by 23
Differential diagnosis of orthostatic hypotension
Lei, L. Y., Chew, D. S., & Raj, S. R. (2020) · Autonomic Neuroscience · doi:10.1016/j.autneu.2020.102713 · Cited by 21
microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers
Titze‐de‐Almeida, R., Titze-de-Almeida, S. S., Ferreira, G. G., Silva, A. P. B., Brandão, P. R. D. P., Oertel, W. H., Schenck, C. H., & Rodrigues, R. N. D. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2020.12.012 · Cited by 21
Nanoplasmonic Sensor Approaches for Sensitive Detection of Disease-Associated Exosomes
Amrollahi, P., Zheng, W., Monk, C. H., Li, C.-Z., & Hu, Y. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00113 · Cited by 22
Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies
Moors, T. E., Mona, D., Luehe, S., Durán-Pacheco, G., Spycher, L., Mundigl, O., Kaluza, K., Huber, S., Hug, M. N., Kremer, T., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01382-z · Cited by 22
Transgenic Mouse Models for the Study of Neurodegenerative Diseases
Marín‐Moreno, A., Canoyra, S., Fernández‐Borges, N., Espinosa, J. C., & Torres, J. M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2801021 · Cited by 21
SNCA Gene Methylation in Parkinson’s Disease and Multiple System Atrophy
Fedotova, E. Y., Iakovenko, E. V., Abramycheva, N. Y., & Illarioshkin, S. N. (2023) · Epigenomes · doi:10.3390/epigenomes7010005 · Cited by 21
The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology
Manecka, D.-L., Vanderperre, B., Fon, E. A., & Durcan, T. M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00311 · Cited by 21
Dynamic footprint based locomotion sway assessment in α-synucleinopathic mice using Fast Fourier Transform and Low Pass Filter
Timotius, I. K., Canneva, F., Minakaki, G., Pasluosta, C. F., Moceri, S., Casadei, N., Rieß, O., Winkler, J., Klucken, J., von Hörsten, S., et al. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.12.004 · Cited by 21
Chronic α-Synuclein Accumulation in Rat Hippocampus Induces Lewy Bodies Formation and Specific Cognitive Impairments
Kasongo, D. W., de Leo, G., Vicario, N., Leanza, G., & Legname, G. (2020) · eNeuro · doi:10.1523/eneuro.0009-20.2020 · Cited by 21
Nasal Rifampicin Improves Cognition in a Mouse Model of Dementia with Lewy Bodies by Reducing α-Synuclein Oligomers
Umeda, T., Hatanaka, Y., Sakai, A., & Tomiyama, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168453 · Cited by 22
Advancing gene therapies, methods, and technologies for Parkinson’s Disease and other neurological disorders
Fiandaca, M. S., Lonser, R. R., Elder, J. B., Ząbek, M., & Bankiewicz, K. S. (2020) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2020.0046 · Cited by 20
PET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 20
Structural network topology and microstructural alterations of the anterior insula associate with cognitive and affective impairment in Parkinson’s disease
Jonkman, L. E., Fathy, Y. Y., Berendse, H. W., Schoonheim, M. M., & van de Berg, W. D. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-95638-8 · Cited by 21
O-Cyclic Phytosphingosine-1-Phosphate Protects against Motor Dysfunctions and Glial Cell Mediated Neuroinflammation in the Parkinson’s Disease Mouse Models
Lee, H. J., Choe, K., Park, J. S., Khan, A., Kim, M. W., Park, T. J., & Kim, M. O. (2022) · Antioxidants · doi:10.3390/antiox11112107 · Cited by 20
Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development
Wang, B., Kobeissy, F. H., Golpich, M., Cai, G., Li, X., Abedi, R., Haskins, W. E., Tan, W., Benner, S. A., & Wang, K. (2024) · Molecules · doi:10.3390/molecules29051124 · Cited by 25
A New Rise of Non-Human Primate Models of Synucleinopathies
Teil, M., Arotçarena, M.-L., & Dehay, B. (2021) · Biomedicines · doi:10.3390/biomedicines9030272 · Cited by 21
Prodromal neuroinvasion of pathological α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy
Ferreira, N., Richner, M., van der Laan, A., Christiansen, I. B. J., Vægter, C. B., Nyengaard, J. R., Halliday, G. M., Weis, J., Giasson, B. I., Mackenzie, I. R., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab104 · Cited by 19
Self-citation
Classification of atypical parkinsonism per pathology versus phenotype
Respondek, G., Stamelou, M., & Höglinger, G. U. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.003 · Cited by 20
Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy
Sorrentino, Z. A., Hass, E. W., Vijayaraghavan, N., Gorion, K.-M. M., Riffe, C. J., Dhillon, J.-K. S., & Giasson, B. I. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135017 · Cited by 19
Elevated Percentage of CD3+ T-Cells and CD4+/CD8+ Ratios in Multiple System Atrophy Patients
Cao, B., Chen, X., Zhang, L., Wei, Q., Liu, H., Feng, W., Chen, Y., & Shang, H. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00658 · Cited by 17
Parkinson's disease susceptibility variants and severity of Lewy body pathology
Heckman, M. G., Kasanuki, K., Diehl, N. N., Koga, S., Soto, A. I., Murray, M. E., Dickson, D. W., & Ross, O. A. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.09.009 · Cited by 19
Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies
Krismer, F., Jellinger, K. A., Scholz, S. W., Seppi, K., Stefanova, N., Antonini, A., Poewe, W. H., & Wenning, G. K. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.05.005 · Cited by 18
Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies
Sandoval, I. M., Marmion, D. J., Meyers, K. T., & Manfredsson, F. P. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212679 · Cited by 20
Advanced brain aging in multiple system atrophy compared to Parkinson’s disease
Chen, C., Kuo, M., Wu, W., Hsu, Y., Wu, R., & Tseng, W. I. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.102997 · Cited by 18
Association of MAPT H1 subhaplotypes with neuropathology of lewy body disease
Heckman, M. G., Kasanuki, K., Brennan, R. R., Labbé, C., Vargas, E. R., Soto, A. I., Murray, M. E., Koga, S., Dickson, D. W., & Ross, O. A. (2019) · Movement Disorders · doi:10.1002/mds.27773 · Cited by 19
Autonomic Dysfunctions in Parkinson’s Disease: Prevalence, Clinical Characteristics, Potential Diagnostic Markers, and Treatment
Zhang, Z., & Chen, S. (2020) · Parkinson s Disease · doi:10.1155/2020/8740732 · Cited by 18
Assessment of TREM2 rs75932628 association with Parkinson’s disease and multiple system atrophy in a Chinese population
Chen, Y., Chen, X., Guo, X., Song, W., Cao, B., Wei, Q., Ou, R., Zhao, B., & Shang, H. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2279-x · Cited by 18
Neuropathological studies of serotonergic and noradrenergic systems in Lewy body disease patients with delusion or depression
Mizutani, M., Sano, T., Ohira, M., & Takao, M. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13436 · Cited by 17
GV ‐971 attenuates α‐Synuclein aggregation and related pathology
Yu, Z., Yang, Y., Chan, R., Shi, M. Y., Stewart, T., Huang, Y. Z., Liu, Z., Lan, G., Sheng, L., Tian, C., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14393 · Cited by 17
Cyclic Ion Mobility-Mass Spectrometry and Tandem Collision Induced Unfolding for Quantification of Elusive Protein Biomarkers
Makey, D. M., Gadkari, V. V., Kennedy, R. T., & Ruotolo, B. T. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00477 · Cited by 18
α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrPC-CCR5 dependent pathway
da Silva, M. I. O., Santejo, M., Babcock, I. W., Magalhães, A., Minamide, L. S., Won, S.-J., Castillo, E., Gerhardt, E., Fahlbusch, C., Swanson, R. A., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06630-9 · Cited by 17
SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population
Xu, Y., Cao, B., Chen, Y., Ou, R., Wei, Q., Yang, J., Zhao, B., Song, W., & Shang, H. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.04.003 · Cited by 17
Analysis of GWAS-linked variants in multiple system atrophy
Gu, X., Chen, Y., Zhou, Q., Lu, Y.-C., Cao, B., Zhang, L., Kuo, M., Wu, Y., Wu, R., Tan, E., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.018 · Cited by 17
Targeting Autophagy In Disease: Recent Advances In Drug Discovery
Kim, D., Hwang, H., & Kwon, H. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1773429 · Cited by 17
Folding Free-Energy Landscape of α-Synuclein (35–97) Via Replica Exchange Molecular Dynamics
Jain, K., Ghribi, O., & Delhommelle, J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01278 · Cited by 19
Dynactin is involved in Lewy body pathology
Shen, C., Honda, H., Suzuki, S. O., Maeda, N., Shijo, M., Hamasaki, H., Sasagasako, N., Fujii, N., & Iwaki, T. (2018) · Neuropathology · doi:10.1111/neup.12512 · Cited by 17
Alpha-synuclein interacts with regulators of ATP homeostasis in mitochondria
Serdiuk, T., Fleischmann, Y., Ghosh, D., Delparente, A., Reber, V., Frey, L., Rhyner, D., Gerez, J., Volkmar, N., Kralickova, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62895-4 · Cited by 16
The Anthocyanidin Peonidin Interferes with an Early Step in the Fibrillation Pathway of α-Synuclein and Modulates It toward Amorphous Aggregates
Verma, G., & Bhat, R. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00726 · Cited by 16
Clinical biomarkers for Lewy body diseases
Abdelmoaty, M. M., Lu, E., Kadry, R., Foster, E. G., Bhattarai, S., Mosley, R. L., & Gendelman, H. E. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01152-x · Cited by 17
Mutant α-synuclein causes death of human cortical neurons via ERK1/2 and JNK activation
Suzuki, H., Egawa, N., Imamura, K., Kondo, T., Enami, T., Tsukita, K., Suga, M., Yada, Y., Shibukawa, R., Takahashi, R., et al. (2024) · Molecular Brain · doi:10.1186/s13041-024-01086-6 · Cited by 16
Sleep in older adults and in subjects with dementia
Frohnhofen, H., Schlitzer, J., & Netzer, N. C. (2017) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-017-1289-0 · Cited by 18

Authors: McCann, H., Stevens, C. H., Cartwright, H., & Halliday, G. M.
Affiliations: Neuroscience Research Australia (AU)
UNSW Sydney (AU)
Corresponding author: Halliday, Glenda M.
ORCID: McCann, Heather
Stevens, Claire H.
Halliday, Glenda M.
Venue: Parkinsonism & Related Disorders
Publisher: Elsevier BV
Published: 2014-01
Volume: 20
Pages: S62-S67
ISSN: 1353-8020 (ISSN-L)
DOI: 10.1016/s1353-8020(13)70017-8
OpenAlex: W2057784346
Cited by: 364
References: 32
Citations by year: 2026: 8 · 2025: 23 · 2024: 55 · 2023: 28 · 2022: 37 · 2021: 43 · 2020: 37 · 2019: 32 · 2018: 23 · 2017: 27 · 2016: 29 · 2015: 17 · 2014: 5
FWCI: 2.22
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Parkinsonism & Related Disorders (publishedVersion)
PubMed (publishedVersion)
UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
Research Online (University of Wollongong) (submittedVersion)
UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
Funders: National Health and Medical Research Council (630434)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: synucleinopathies, alpha-synuclein aggregation
MeSH terms: Humans, Parkinson Disease, Phenotype, Multiple System Atrophy, Lewy Body Disease, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

α-Synucleinopathy phenotypes

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks